MENU
+Compare
XCUR
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$4.75
Change
-$0.25 (-5.00%)
Capitalization
30.01M

XCUR Exicure Inc Forecast, Technical & Fundamental Analysis

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets... Show more

XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XCUR with price predictions
Sep 04, 2025

XCUR's Stochastic Oscillator is sitting in oversold zone for 12 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XCUR advanced for three days, in of 202 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XCUR as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XCUR turned negative on August 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XCUR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XCUR entered a downward trend on September 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.386) is normal, around the industry mean (19.994). P/E Ratio (0.187) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (23.641) is also within normal values, averaging (325.279).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XCUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XCUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XCUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company, which engages in the provision of clinical stage biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2430 N. Halsted Street
Phone
+1 847 673-1700
Employees
13
Web
https://www.exicuretx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FACT10.28N/A
N/A
Fact II Acquisition Corp
RACE488.77-6.42
-1.30%
Ferrari NV
RVPH0.44-0.01
-1.75%
Reviva Pharmaceuticals Holdings
BOW31.05-1.00
-3.12%
Bowhead Specialty Holdings Inc
BRBR39.46-3.22
-7.54%
BellRing Brands

XCUR and Stocks

Correlation & Price change

A.I.dvisor tells us that XCUR and VSTM have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XCUR and VSTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
-2.53%
VSTM - XCUR
28%
Poorly correlated
+11.16%
AMGXF - XCUR
27%
Poorly correlated
N/A
NBY - XCUR
25%
Poorly correlated
+57.46%
ERNA - XCUR
23%
Poorly correlated
-10.62%
FATE - XCUR
22%
Poorly correlated
-2.71%
More